The median time to response to treatment was 1 month, and
the median duration of response was longer than 1 year (13.6 months).
The study has yet to determine
the median duration of response.
Median duration of response had not been reached after a median follow up of 35.7 months (range: 14.1 to 44.9 months).
Patients in cohort A had
a median duration of response longer than 1 year (14.7 months); the median duration of response in cohort B was 4.6 months and in cohort C was not estimable.
Median duration of response had not been reached in the nivolumab plus ipilimumab arm; it was 31.1 months and 18.2 months for the nivolumab plus placebo arm and ipilimumab - alone arm, respectively.
Median duration of response was not yet reached.
The median time to response with combination therapy was 2 months, with
a median duration of response of 14.2 months.
The median duration of response for patients who responded to pembrolizumab has not been reached, while
the median duration of response for patients who responded to chemotherapy was only 4.3 months.
The response rate for patients treated on the chemotherapy arm was 33.5 percent, but
median duration of response was just 5.7 months before disease progression.
Not exact matches
«Patients who respond to immunotherapy tend to continue their
responses for long
durations, and these lengthier
responses are cut off in calculations
of median overall survival,» she says.
The study reported a
median time to
response to treatment
of 1 month, with the
duration of treatment 13.6 months.
While the
duration of response in the velimogene aliplasmid responders was marginally longer than with DTIC / TMZ (P =.066), overall survival was shorter (
median, 18.8 months [95 % CI, 16.6 — 21.3 months] vs 24.1 months [95 % CI, 17.1 — 27.9 months]; P =.491).